ImmunoGen, Inc. (IMGN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Waltham, MA, United States. Der aktuelle CEO ist Mark Joseph Enyedy.
IMGN hat IPO-Datum 1989-11-17, 277 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $8.73B.
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies for cancer treatment. The company's lead candidate, mirvetuximab soravtansine, targets folate-receptor alpha and is in Phase III trials for platinum-resistant ovarian cancer, while Pivekimab sunirine, a CD123-targeting ADC, is in Phase II development for acute myeloid leukemia and related blood cancers. ImmunoGen maintains a robust pipeline of preclinical programs and strategic collaborations with major pharmaceutical companies including Roche, Amgen, Bayer, Eli Lilly, Novartis, and others. Founded in 1980 and headquartered in Waltham, Massachusetts, the company leverages proprietary ADC technology to advance novel cancer therapies.
